At the news
? BEARISHIMPACT 5/10 S-3ASR filed Nov 13, 2026 at 16:25 ET
Inhibrx filed an automatic shelf registration (S-3ASR) and a prospectus supplement for an at-the-market (ATM) equity offering of up to $150M in common stock, with Stifel and LifeSci Capital as sales agents. The filing coincides with the same-day release of Q3 2026 results showing a net loss of $38.7M, cash of $199.5M, and $275M in outstanding debt, indicating the company needs capital to fund clinical development and potential commercialization of ozekibart ahead of a BLA filing.
- S-3ASR filed November 13, 2026 for up to $150M in common stock via ATM offering
- Sales agents: Stifel, Nicolaus & Company and LifeSci Capital; commission up to 3.0%
- Q3 2026 net loss of $38.7M ($2.46/share) vs $35.3M ($2.28/share) in Q3 2025
- Cash and cash equivalents of $199.5M as of September 30, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access